Aptinyx Inc. got a lot accomplished with its pipeline of small molecule NMDA receptor modulators after it closed a $65m Series A venture capital round in May 2016. So, with several key milestones met, the company revealed on Dec. 18 that it has raised a $70m Series B round to support its new goals.
President and CEO Norbert Riedel told Scrip that Aptinyx kept three goals in mind when it sought backers for the...






